All Clinical Trials

Clinical Trial NCT03746483

OPTION: A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to assess the Safety and Efficacy of MS1819-SD in Patients with Exocrine Pancreatic with Insufficiency due to Cystic Fibrosis

  • ClinicalTrials.gov ID: NCT03746483
  • Recruiting participants (Starts Jan. 1, 2019)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: MEGHANA NITIN SATHE

summary

The primary objectives of this study is to assess the safety and efficacy of MS1819 in enteric capsules vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF)

objective

The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PeRT) in patients with exocrine pancreatic insufficiency (ePi) due to cystic fibrosis (CF).

If you are interested in this clinical trial, please contact Daniyal Kamal on the Children’s Health Research Team.Call 214-456-5489Email